Avidity Partners Management’s Karyopharm Therapeutics KPTI Stock Holding History
Bought
Maintained
Sold
Other funds holding KPTI
ACA
Avidity Partners Management's KPTI Position: Q3 2026 in Review
Avidity Partners Management reduced its Karyopharm Therapeutics (KPTI) stake by 4.3% in Q3 2026, selling an estimated $162K and leaving 884,900 shares worth $1.08M. The position accounts for 0.22% of the portfolio, ranked #15.
Avidity Partners Management first reported a position in KPTI in Q4 2022 and has held it in 16 quarters since. The position peaked at $37.5M in Q1 2023. 92 funds tracked by Wall St. Rank hold KPTI as of Q3 2026.
- Avidity Partners Management held 884,900 shares of Karyopharm Therapeutics worth $1.08M as of Q3 2026.
- Avidity Partners Management sold 39,587 Karyopharm Therapeutics shares in Q3 2026, an estimated $162K.
- Karyopharm Therapeutics made up 0.22% of Avidity Partners Management's portfolio in Q3 2026, its #15 holding.
- Avidity Partners Management first reported a position in Karyopharm Therapeutics in Q4 2022 and has held it in 16 quarters since.
- Avidity Partners Management's Karyopharm Therapeutics position peaked at $37.5M in Q1 2023.
- 92 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2026.
Based on Avidity Partners Management's 13F filing for Q3 2026, filed 16 Nov 2026.